Modern oncology is witnessing a therapeutic revolution as bispecific antibodies redefine treatment possibilities in Non-Small Cell Lung Cancer (NSCLC) treatment. These engineered therapeutic proteins represent the culmination of decades of immunotherapy research, offering patients access to treatment strategies that simultaneously target multiple cancer vulnerabilities with unprecedented precision and efficacy. Therapeutic Innovation Through Dual Mechanisms The Read.